4//SEC Filing
Milligan John C.K. IV 4
Accession 0001387131-18-006855
CIK 0000025743other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 8:01 PM ET
Size
16.3 KB
Accession
0001387131-18-006855
Insider Transaction Report
Form 4
Milligan John C.K. IV
DirectorPresident, Secretary, Director10% Owner
Transactions
- Exercise/Conversion
Common Stock
2018-12-18$0.10/sh+129,127$13,145→ 1,601,546 total - Sale
Common Stock
2018-12-17$3.75/sh−129,000$483,750→ 1,472,419 total - Exercise/Conversion
Common Stock
2018-12-17$0.10/sh+129,000$13,132→ 1,601,419 total - Sale
Common Stock
2018-12-18$3.64/sh−129,127$469,635→ 1,472,419 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2018-12-17−129,000→ 129,127 totalExercise: $0.10From: 2012-01-01Exp: 2019-01-01→ Common Stock (129,000 underlying) - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2018-12-18−129,127→ 0 totalExercise: $0.10From: 2012-01-01Exp: 2019-01-01→ Common Stock (129,127 underlying)
Holdings
- 3,557,373(indirect: See footnote)
Common Stock
- 434,814(indirect: See footnote)
Common Stock
Footnotes (5)
- [F1]The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.87, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.53 to $3.735, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]By the Milligan Irrevocable Nonexempt Trust - 2014. These securities are held in a trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F5]By John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.
Documents
Issuer
TherapeuticsMD, Inc.
CIK 0000025743
Entity typeother
Related Parties
1- filerCIK 0001532230
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 8:01 PM ET
- Size
- 16.3 KB